Currently, several strategies involving the combination of BCL6 inhibitors with several agents, including PRMT5 inhibitors [39], EZH2 inhibitors [38], STAT3 inhibitors [51] and chemotherapy drug doxorubicin [27], have been explored for the treatment of lymphomas. This evidence concerns the gene STAT3 and lymphoma.